IGEM:Stanford/2009/Meetings/6/29/09
Progress
- Context: specific disease targeted for therapy (IBD)
- Mechanism: designed as a therapeutic probiotic
- Project details fleshed out at the systems, device, and parts level
- Identification of first- and second-order problems
- Five plasmids designed:
primers sequenced for 10 genes
specific gene sequences identified
First-order problems
- Systems level
Extent of imbalance between Tregs and Th17 cells in IBD Predicting the degree of change our device will enact on Th17:Treg ratio Decide on ideal chassis; current possibilities: Nissile 1917, Bactoblood, CFB
- Device/Parts level
Background noise disrupting functionality of Trp operon (in vivo challenge) [trp] for which the immuosuppression device must be functional Engineer protease binding space for plasmid containing IL-6/signal peptide
Second-order problems
- System level
An embedded off/kill mechanism Sustainability of our therapy population, esp. with regard to competition with microbiota already inhabiting the gut Determine the extent to which Berkeley’s modifications apply to our device
- Device/Parts level
Soxr protein sensitivity to NO Terminator efficiencies
- Parts level
IL-6 export and cleavage, functionality compared to hIL-6
Tasks to be completed in upcoming week
- Design a dynamic illustration of our machine, to be posted on the wiki
- Address first-order problems
- Organize lab space
- Update the wiki—build infrastructure for experimental log
- Send out sequences to be constructed